<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00094445</url>
  </required_header>
  <id_info>
    <org_study_id>ID03-0009</org_study_id>
    <secondary_id>1R21CA104337</secondary_id>
    <secondary_id>NCI-2012-01309</secondary_id>
    <nct_id>NCT00094445</nct_id>
  </id_info>
  <brief_title>Trial of Curcumin in Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase II Trial of Curcumin in Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sabinsa Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if treatment with curcumin can help&#xD;
      shrink or slow the growth of pancreatic cancers. The effect of curcumin on the way pancreatic&#xD;
      cancer cells function and the safety of treatment with curcumin will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Curcumin, a yellow substance extracted from the plant Curcuma longa, is commonly used as a&#xD;
      food additive. It is a natural anti-inflammatory compound and has shown anti-tumor activity&#xD;
      in the laboratory. During this study, you will receive much higher doses of curcumin than can&#xD;
      be obtained from the diet.&#xD;
&#xD;
      During the study, you will receive curcumin by mouth every day. You will be required to take&#xD;
      up to 16 pills per day each morning. Every 8-week period you take curcumin is considered a&#xD;
      &quot;course&quot; of treatment. The number of courses you receive depends on how you are responding to&#xD;
      treatment. You can continue treatment as long as the disease does not get worse. If the&#xD;
      disease gets worse or you experience any intolerable side effects, you will be taken off the&#xD;
      study and your doctor will discuss other treatment options with you.&#xD;
&#xD;
      You will be given a questionnaire to complete at the beginning of the study and once a week&#xD;
      while you are on therapy to help the medical staff understand how the different symptoms from&#xD;
      your disease are affecting you. This questionnaire, which should take about 5 minutes to&#xD;
      complete, can be done over the telephone or with the help of one of the study staff during&#xD;
      your visits.&#xD;
&#xD;
      At the end of each course of treatment (every 8 weeks), you will have a physical exam and the&#xD;
      tumor will be re-evaluated using CT scans and/or blood (about 2 tablespoons) tests.&#xD;
&#xD;
      This is an investigational study. Curcumin is a commercially available substance, which is&#xD;
      commonly used as a food additive. Up to 50 participants will take part in this study. All&#xD;
      will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six-Month Participant Survival</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Number of participants followed from baseline (date of randomization) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral curcumin daily for eight weeks, starting dose 8 gm per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Starting dose 8 gm orally per day for 8 weeks. If patient experiences grade III toxicity, dose held and restarted with a 50% dose reduction after resolution of toxicity to &lt;/= Grade I. Patients with grade IV toxicity will discontinue treatments. Patients with &lt;/= grade I toxicity may have a 25% dose increase at each four-week period. Patients will continue on treatment until disease progresses, unless Grade III toxicity supervenes.</description>
    <arm_group_label>Curcumin</arm_group_label>
    <other_name>diferuloyl methane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient has pathologically confirmed adenocarcinoma of the pancreas that is not&#xD;
             amenable to curative surgical resection (includes locally advanced, metastatic, or&#xD;
             recurrent disease). Histology must be confirmed by the pathology department of the&#xD;
             investigational center.&#xD;
&#xD;
          2. The patient has a Karnofsky Performance Status of greater than or equal to 60 at study&#xD;
             entry.&#xD;
&#xD;
          3. The patient has given informed consent.&#xD;
&#xD;
          4. The patient is at least 18 years of age.&#xD;
&#xD;
          5. The patient has adequate hematologic function as defined by an absolute neutrophil&#xD;
             count greater than or equal to 1,500/mm3, platelet count greater than or equal to&#xD;
             100,000/mm3.&#xD;
&#xD;
          6. The patient has adequate hepatic function as defined by a total bilirubin less than or&#xD;
             equal to 2.0 X ULN, alkaline phosphatase, AST and/or ALT less than or equal to 5 X&#xD;
             ULN, and creatinine less than or equal to 2.0 mg/dL.&#xD;
&#xD;
          7. The patient has measurable disease.&#xD;
&#xD;
          8. The patient agrees to use effective contraception if procreative potential exists.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient has a history of treated or active brain metastases, carcinomatous&#xD;
             meningitis, an uncontrolled seizure disorder, or active neurological disease.&#xD;
&#xD;
          2. The patient has received prior radiation. Patients with measurable disease outside the&#xD;
             radiation port or documented disease progression of previously irradiated measurable&#xD;
             disease are eligible. Patient must be greater than or equal to four weeks post-therapy&#xD;
             and have recovered from all toxicities.&#xD;
&#xD;
          3. The patient has an unstable medical condition according to the investigator, including&#xD;
             uncontrolled diabetes mellitus or hypertension; active infections requiring systemic&#xD;
             antibiotics, antivirals, or antifungals, unstable CHF, uncontrolled arrythmias, or&#xD;
             unstable coagulation disorders.&#xD;
&#xD;
          4. The patient is pregnant (confirmed by serum Beta-HCG) or is breast feeding.&#xD;
&#xD;
          5. The patient has received an investigational agent(s) within four weeks of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Subbiah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <reference>
    <citation>Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003 Jan-Feb;23(1A):363-98. Review.</citation>
    <PMID>12680238</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 18, 2004</study_first_submitted>
  <study_first_submitted_qc>October 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2004</study_first_posted>
  <results_first_submitted>August 13, 2020</results_first_submitted>
  <results_first_submitted_qc>August 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2020</results_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Adenocarcinoma of the pancreas</keyword>
  <keyword>Alternative therapy</keyword>
  <keyword>Pancreas</keyword>
  <keyword>Pancreatic Neoplasm</keyword>
  <keyword>Cancer of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: November 12, 2004 to November 11, 2010. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>1 participant did not receive treatment due to screen failure, patient withdrew the consent</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Curcumin</title>
          <description>Oral curcumin daily for eight weeks, starting dose 8 gm per day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Curcumin</title>
          <description>Oral curcumin daily for eight weeks, starting dose 8 gm per day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="40" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Six-Month Participant Survival</title>
        <description>Number of participants followed from baseline (date of randomization) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Curcumin</title>
            <description>Oral curcumin daily for eight weeks, starting dose 8 gm per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Six-Month Participant Survival</title>
          <description>Number of participants followed from baseline (date of randomization) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Curcumin</title>
          <description>Oral curcumin daily for eight weeks, starting dose 8 gm per day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Multiple pulmonary emboli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI hemmorhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>chronic cancer progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>abdomen pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>metastasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Chronic colocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>indigestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>non-neutropenic fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>slurred speech</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>mood alteration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vivek Subbiah, MD / Assistant Professor, Investigational Cancer Therapeutics</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-563-0393</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

